Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.

Huls, Gerwin; Mulder, André B; Rosati, Stefano; van de Loosdrecht, Arjan A; Vellenga, Edo; de Wolf, Joost T M

Huls, Gerwin; Mulder, André B; Rosati, Stefano; van de Loosdrecht, Arjan A; Vellenga, Edo; de Wolf, Joost T M.

Affiliation

Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, The Netherlands. g.huls@int.umcg.nl

Blood ; 116(2): 180-2, 2010 Jul 15.

Article in En | MEDLINE | ID: mdl-20194893

Subject(s)

Anemia, Refractory/drug therapy; Anemia, Sideroblastic/drug therapy; Antineoplastic Agents/therapeutic use; Janus Kinase 2/genetics; Thalidomide/analogs & derivatives; Thrombocytosis/drug therapy; Aged, 80 and over; Anabolic Agents/therapeutic use; Anemia, Refractory/genetics; Anemia, Sideroblastic/genetics; Erythropoietin/therapeutic use; Humans; Hypertension, Pulmonary/complications; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism/complications; Pyridoxine/therapeutic use; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide/therapeutic use; Thrombocytosis/genetics; Vitamin B Complex/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Thrombocytosis / Anemia, Refractory / Janus Kinase 2 / Anemia, Sideroblastic / Antineoplastic Agents Limits: Aged80 / Humans / Male / Middle aged Language: En Journal: Blood Year: 2010 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google